☑特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 □其他（请文字说明其他活动内容） 参与单位名称及 证券代码：002872 证券简称：天圣制药 天圣制药集团股份有限公司 投资者关系活动记录表 编 号 ： 2018- 003 海南旭日盛德资产管理有限公司:杜小东、毛云强 | --- | --- | --- | |-----------------------------|----------------------------------------------|-------| | 人员姓名 | | | | 时间 | 2018 年 12 月 28 日 | | | 地点 | 公司会议室 | | | 上市公司接待人 | 董事会秘书王琴女士及其他相关人员。 | | | 员姓名 | | | | | | | | 投资者关系活动 主要内容介绍 | 一、签署《承诺书》 | | | | 二、介绍公司基本情况，播放公司宣传片 | | | | 三、问答环节 | | | | 1 、贵公司目前医药流通、医药制造的经营情况？ | | | --- | --- | |--- ...

Revenue and Profit - Revenue for Q3 2022 was CNY 134,403,839.25, an increase of 25.81% compared to the same period last year, but a decrease of 32.75% year-to-date[5] - Net profit attributable to shareholders was CNY -16,089,574.72, a decrease of 41.19% year-on-year, with year-to-date net profit at CNY -62,581,998.01, a decrease of 7.75%[5] - Basic and diluted earnings per share were both CNY -0.0506, reflecting a 41.16% increase compared to the same period last year[5] - Total operating revenue for the third quarter was ¥404,752,141.46, a decrease of 32.7% compared to ¥601,836,443.54 in the same period last year[35] - The net profit for Q3 2022 was -63,392,713.81 CNY, compared to -68,377,178.62 CNY in Q3 2021, showing an improvement of approximately 5.8%[37] - Operating profit for Q3 2022 was -66,947,544.68 CNY, slightly better than -71,640,936.42 CNY in the same period last year, indicating a reduction in losses[37] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,923,952,844.88, a decrease of 6.28% from the end of the previous year[5] - Total assets decreased to ¥2,923,952,844.88 from ¥3,120,025,480.00, a decline of 6.3%[34] - Total liabilities decreased to ¥708,099,475.96 from ¥840,788,050.92, a reduction of 15.7%[34] - Non-current assets totaled ¥2,181,834,274.98, slightly down from ¥2,199,819,344.70, a decrease of 0.8%[33] Cash Flow - Cash flow from operating activities showed a net outflow of CNY -56,016,269.70, a decrease of 59.07% year-to-date[5] - Cash flow from operating activities for Q3 2022 was -56,016,269.70 CNY, worsening from -35,213,819.19 CNY in Q3 2021[41] - The total cash inflow from operating activities was 517,284,153.11 CNY in Q3 2022, compared to 734,803,797.98 CNY in Q3 2021, indicating a decrease of approximately 29.7%[41] - The company reported a total cash outflow from operating activities of 573,300,422.81 CNY in Q3 2022, down from 770,017,617.17 CNY in Q3 2021, showing a reduction in cash outflow[41] - Cash flow from investing activities was -137,744,562.43 CNY in Q3 2022, compared to -27,548,033.66 CNY in Q3 2021, indicating increased cash outflow for investments[41] Shareholder Information - The total number of common shareholders at the end of the reporting period is 14,999[21] - The largest shareholder, Liu Qun, holds 32.89% of the shares, amounting to 104,590,532 shares, with 35,000,000 shares pledged[21] - The second-largest shareholder, Chongqing Yudian State-owned Assets Management Co., Ltd., holds 4.34% of the shares, totaling 13,792,255 shares[21] - The top ten shareholders do not participate in margin financing[22] Legal and Regulatory Issues - The company is involved in a significant legal case regarding bribery, with the final judgment still uncertain[23] - The company has faced risk warnings due to the controlling shareholder's legal issues, impacting stock trading[25] - Liu Qun, the controlling shareholder, has repaid a total of 121.47 million yuan for misappropriated funds, including interest of approximately 15.51 million yuan[26] - The company has a total of 12,147,492.6 thousand yuan in funds that were misappropriated and subsequently repaid[26] - The company will continue to monitor the legal case and fulfill disclosure obligations as necessary[29] Operational Performance - Operating cash flow net outflow increased by 59.07% year-on-year, primarily due to the payment of cash for maturing notes payable[19] - Revenue from other income decreased by 46.92% year-on-year, mainly due to a reduction in government subsidies received[17] - The company reported a net profit margin decline due to increased sales and management expenses, with sales expenses at ¥167,625,294.81 compared to ¥203,837,679.61 last year[35] - Research and development expenses were ¥21,025,824.25, showing a slight decrease from ¥21,796,128.51 year-on-year[35] - The company's cash and cash equivalents decreased to ¥148,602,558.08 from ¥338,675,754.54, representing a decline of 56.2%[32] - Accounts receivable decreased to ¥137,371,263.04 from ¥167,320,974.39, a reduction of 17.9%[32] - Inventory increased to ¥141,577,855.57 from ¥124,583,351.75, reflecting a rise of 13.7%[33] - Short-term borrowings decreased by 32.59% compared to the beginning of the year, as part of the repayment of short-term loans[11]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥270,348,302.21, a decrease of 45.38% compared to ¥495,001,560.78 in the same period last year[24]. - The net loss attributable to shareholders was ¥46,492,423.29, representing a 14.85% increase in loss from ¥40,479,749.05 in the previous year[24]. - The basic and diluted earnings per share were both -¥0.1462, a decline of 14.85% from -¥0.1273 in the previous year[24]. - The total revenue for the first half of 2022 was 107,879 million, a decrease from 79,869 million in the previous period[77]. - The net profit for the first half of 2022 was a loss of CNY 47,031,793.65, compared to a loss of CNY 40,959,839.83 in the first half of 2021, indicating a deterioration of approximately 14.5%[188]. - The total comprehensive income for the first half of 2022 was CNY -47,031,793.65, compared to CNY -40,959,839.83 in the first half of 2021, reflecting a decline of approximately 14.5%[188]. Cash Flow and Investments - The net cash flow from operating activities improved by 20.80%, amounting to -¥53,554,623.52 compared to -¥67,621,441.88 in the previous year[24]. - The company reported a net cash flow from operating activities of -¥53,554,623.52, an improvement of 20.82% compared to -¥67,621,441.88 in the previous year[56]. - The net cash flow from investment activities was -94,598,710.31 CNY for the first half of 2022, worsening from -30,213,541.00 CNY in the same period of 2021[194]. - The net cash flow from financing activities was 45,882,460.45 CNY in the first half of 2022, a turnaround from -30,907,321.76 CNY in the first half of 2021[194]. - The company reported a significant increase in cash inflow from the recovery of investments, reaching 522,683,019.82 CNY in the first half of 2022, compared to 94,758,332.37 CNY in the same period of 2021[195]. Assets and Liabilities - Total assets decreased by 5.88% to ¥2,936,651,899.84 from ¥3,120,025,480.00 at the end of the previous year[24]. - The company's total assets decreased from ¥338,675,754 to ¥196,832,810, with a notable reduction in cash and cash equivalents from 10.85% to 6.70% of total assets[62]. - The company's long-term borrowings decreased from ¥155,373,643 to ¥109,504,282, reflecting a 1.25% reduction in the proportion of total liabilities[62]. - The total liabilities decreased to ¥1,200,000,000.00, reflecting a reduction in financial obligations[178]. - The company's non-current liabilities due within one year increased from ¥53,626,474.2 to ¥113,329,162.0, reflecting a rise of 2.14%[63]. Research and Development - Research and development expenses increased by 9.15% to ¥14,050,556.75 from ¥12,872,350.45, indicating a continued focus on innovation[56]. - The company has established a research institute focusing on innovative drugs, improved new drugs, and deep development of traditional Chinese medicine, attracting top research talent[40]. - The company aims to increase its R&D investment by 10% in the upcoming fiscal year to support innovation[199]. Market and Industry Outlook - The pharmaceutical industry is expected to grow due to increasing chronic disease prevalence and supportive government policies[33]. - The company is engaged in drug research, production, and sales, with a focus on modernizing traditional Chinese medicine[34]. - The company has seen a rise in market demand for traditional Chinese medicine, driven by recent policy support and integration with Western medicine[34]. - The company is facing risks related to industry policies, including stricter regulations and price controls, which could impact future growth[86]. Corporate Governance and Compliance - The company emphasizes strict compliance with laws and regulations to protect the rights of shareholders and creditors, enhancing corporate governance and internal control systems[113]. - The company has implemented a system for managing insider information to ensure fair and transparent information disclosure practices[113]. - The company is currently involved in a significant legal case regarding bribery allegations, which may affect its operations and financial standing[90]. Environmental Responsibility - The company is classified as a key pollutant discharge unit by environmental protection authorities[102]. - The company reported that all monitored pollutants were within the permitted discharge limits, with no exceedances noted[102]. - The company has established a comprehensive emergency response plan for environmental incidents, which has been reviewed and filed by experts[108]. Shareholder Information - The company raised a total of RMB 1,185.61 million through the issuance of 53 million shares at a price of RMB 22.37 per share, with a net amount of RMB 1,078.79 million after expenses[74]. - The total number of shares is 318,000,000, with 100% ownership by the shareholders[161]. - Liu Qun holds 32.89% of the total shares, amounting to 104,590,532 shares, with 1,628,800 shares pledged[164]. Related Party Transactions - The total amount of related party transactions in the first half of 2022 was approximately 131.7 million yuan, accounting for 1.40% of similar transactions[135]. - The company reported a receivable from related parties of 162.81 million yuan, with a year-end balance of 147.47 million yuan[140]. - The company did not experience significant differences between transaction prices and market reference prices in related party transactions[137].

Financial Performance - The company's operating revenue for 2021 was approximately ¥736.69 million, a decrease of 38.75% compared to ¥1.20 billion in 2020[22]. - The net profit attributable to shareholders was a loss of approximately ¥67.81 million, an improvement of 86.18% from a loss of ¥490.73 million in the previous year[22]. - The net cash flow from operating activities was approximately ¥18.97 million, down 90.00% from ¥189.75 million in 2020[22]. - The basic and diluted earnings per share were both -¥0.2132, showing an improvement of 86.18% from -¥1.5432 in 2020[22]. - The weighted average return on net assets was -2.94%, an increase of 84.17% compared to -18.57% in the previous year[22]. - Total assets decreased by 14.42% to CNY 3,120,025,480 in 2021 from CNY 3,645,939,804 in 2020[23]. - Operating revenue fell to CNY 736,685,771.58 in 2021, down 38.67% from CNY 1,202,746,111.67 in 2020[23]. - The company reported a total operating cost of ¥432,703,168.61, down 49.26% from ¥852,832,386.69 in 2020[65]. - The company reported a total revenue of ¥180,130,258.34 from its major customers, representing 24.45% of total revenue[70]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the fiscal year 2021, representing a year-over-year growth of 20%[152]. Cash Flow and Investments - The company plans not to distribute cash dividends or issue bonus shares[7]. - The company reported a net cash flow from investment activities turned positive at CNY 169,580,103.50, a change of 322.69% from a negative CNY 76,149,757.19 last year[76]. - Cash and cash equivalents increased by 336.48% to CNY 49,582,224.84 compared to a decrease of CNY 20,966,904.02 in the previous year[76]. - The total investment amount for the reporting period was ¥127,082,593.70, a decrease of 25.81% compared to ¥171,299,508.86 in the previous year[85]. - The company utilized RMB 7,605.26 million of the raised funds for investment projects during the reporting period, with a remaining balance of RMB 8,190.40 million in the special account as of December 31, 2021[93]. - The company has invested RMB 5,169.89 million in the Tian Sheng (Chongqing) modern pharmaceutical logistics headquarters base project, achieving 87.10% of the investment progress[94]. Research and Development - The company focuses on the development of new raw materials and formulations for anesthetics, bacterial infections, and metabolic diseases, achieving significant results in 2021[38]. - The company has established a research institute that employs a project team model for R&D, attracting top scientific talent for innovative and improved drug development[37]. - R&D investment amounted to ¥29,246,325.10, representing 3.97% of operating revenue, up from 1.87% in the previous year[75]. - The company plans to increase R&D investment in traditional Chinese medicine and chemical drugs, focusing on high-end and basic products[106]. - Investment in R&D increased by 30% in 2021, focusing on innovative drug development and new technologies[152]. Market and Product Development - The company has over 300 approved drug varieties, covering both traditional Chinese medicine and chemical drugs[33]. - The company has several best-selling products, including pediatric cough granules and blood-activating injection solutions, which are included in the national essential drug list[33]. - The company is positioned to benefit from the growing demand for healthcare products driven by an aging population and increasing health awareness[31]. - The company is actively expanding its product line with multiple projects in various stages of development, including consistency evaluations and production approvals[74]. - The company introduced three new products in 2021, contributing to 10% of total revenue[152]. Governance and Compliance - The company emphasizes the importance of risk awareness regarding future plans and strategies[6]. - The company has established a transparent performance evaluation and incentive mechanism for its board and management, ensuring compliance with legal regulations[133]. - The board of directors consists of 7 members, including 3 independent directors, ensuring a balanced governance structure[130]. - The company has implemented measures to protect the rights of minority shareholders during general meetings, including separate voting for significant matters[127]. - The company has actively monitored external environmental changes affecting its operations[159]. Environmental Responsibility - The company is classified as a key pollutant discharge unit and has reported no exceedance of pollution discharge standards[190]. - The company operates a wastewater treatment facility that processes cleaning wastewater, ensuring compliance with discharge standards[193]. - The company has established an emergency response plan for environmental incidents, enhancing its risk management capabilities[195]. - The company adheres to environmental protection requirements during construction projects, ensuring compliance with impact assessments[194]. - The company invested a total of 185,700 CNY in the construction of a traditional Chinese medicine planting base project to support poverty alleviation efforts[199]. Legal and Regulatory Issues - The company is currently under scrutiny due to ongoing legal proceedings against Liu Qun, with the final judgment still uncertain[128]. - The company was fined a total of RMB 3.8 million for bribery-related charges, with RMB 3 million for unit bribery and RMB 800,000 for bribery to a unit[118]. - The controlling shareholder, Liu Qun, has repaid a total of CNY 121.47 million in misappropriated funds, including interest of CNY 15.51 million, by April 8, 2021[184]. - The company has maintained compliance with regulations regarding the management and disclosure of raised funds[98]. Employee Management - The total number of employees at the end of the reporting period is 1,307, with 548 from the parent company and 605 from major subsidiaries[164]. - Employee training is prioritized, with a structured training system in place to enhance professional skills and support company growth[167]. - The company emphasizes a fair and transparent compensation policy, adhering to labor laws and focusing on performance-based incentives[166]. - The educational background of employees shows that 876 have vocational education or below, 251 have associate degrees, 171 hold bachelor's degrees, and 9 have master's degrees[164]. Future Outlook - The company provided a positive outlook for 2022, projecting a revenue growth of 25% based on new product launches and market expansion strategies[152]. - Future outlook remains positive with expectations of continued revenue growth and market expansion initiatives[144]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2023[152].

Financial Performance - The company's operating revenue for Q1 2022 was ¥135,352,879.35, a decrease of 59.48% compared to ¥334,030,966.92 in the same period last year[2] - The net profit attributable to shareholders was a loss of ¥15,756,573.03, an improvement of 37.71% from a loss of ¥25,296,030.22 year-on-year[2] - Basic and diluted earnings per share improved by 37.74%, both standing at -¥0.0495 compared to -¥0.0795 in the previous year[2] - The company reported a significant decrease in sales expenses to ¥57,312,574.16, down from ¥90,266,812.17 in the previous period, reflecting cost-cutting measures[19] - The company recorded a total comprehensive loss of -¥16,107,018.96, compared to -¥25,263,753.07 in the previous period[21] Cash Flow - The net cash flow from operating activities increased by 130.70%, reaching ¥8,970,094.74, compared to a negative cash flow of ¥29,219,215.98 in the previous year[2] - Cash flow from operating activities shows a net inflow of ¥8,970,094.74, compared to a net outflow of -¥29,219,215.98 in the previous period[24] - The net cash flow from financing activities was 12,815,643.92, compared to a negative cash flow of 8,139,738.16 in the previous period[25] - The net increase in cash and cash equivalents was -69,731,878.22, compared to -14,960,165.71 in the previous period[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,099,191,049.63, a slight decrease of 0.67% from ¥3,120,025,480.00 at the end of the previous year[2] - The company's current assets totaled CNY 905,832,895.16, slightly down from CNY 920,206,135.30 at the beginning of the year, indicating a decrease of approximately 1.5%[16] - Total liabilities decreased to CNY 836,061,269.02 from CNY 840,788,050.92, a slight decline of around 0.3%[17] - The company's equity attributable to shareholders decreased to CNY 2,257,674,459.83 from CNY 2,273,431,662.37, a decrease of approximately 0.7%[18] Investments and Receivables - The increase in other receivables by 136.50% was primarily due to loans made to Chongqing Yichang Changsheng Pharmaceutical Co., Ltd[5] - The company reported a significant increase in other receivables, which rose to CNY 188,023,380.33 from CNY 79,502,613.98, indicating an increase of approximately 135%[16] - Cash inflow from investment activities totals ¥130,424,863.54, an increase from ¥71,419,320.73 in the previous period[24] - Cash outflow from investment activities is ¥221,942,480.42, significantly higher than ¥49,020,532.30 in the previous period[24] Legal and Compliance - The company is currently involved in a legal case regarding bribery, with a fine of ¥3.8 million imposed, and the final judgment remains uncertain[10] Research and Development - The company has increased R&D expenses to ¥7,291,377.71, up from ¥6,091,352.39 in the previous period, indicating a focus on innovation[19] Miscellaneous - The company disposed of a piece of land, resulting in a non-operating income of ¥6,880,379.69[7] - The first quarter report was not audited[26]

Financial Performance - The company's operating revenue for the third quarter was ¥106,834,882.76, a decrease of 63.21% compared to the same period last year[3]. - The net profit attributable to shareholders was -¥27,356,755.05, representing a 46.16% increase in losses year-over-year[3]. - Total operating revenue for Q3 2021 was CNY 601.84 million, a decrease of 33.2% compared to CNY 900.11 million in the same period last year[29]. - Net loss for Q3 2021 was CNY 68.38 million, compared to a net loss of CNY 125.83 million in Q3 2020, representing a 45.6% improvement[30]. - The company's gross profit margin for Q3 2021 was approximately 38.4%, compared to 28.0% in the same period last year[29]. - The basic and diluted earnings per share for Q3 2021 were both CNY -0.2133, an improvement from CNY -0.3752 in Q3 2020[31]. Cash Flow and Liquidity - The net cash flow from operating activities was -¥35,213,819.19, a decrease of 126.40% year-to-date[3]. - The total cash inflow from operating activities was approximately CNY 734.80 million, a decrease from CNY 1,292.58 million in the previous year, reflecting a decline of about 43%[34]. - The net cash outflow from operating activities was CNY -35.21 million, compared to a net inflow of CNY 133.40 million in the same period last year[34]. - The cash inflow from financing activities was CNY 220.06 million, while the cash outflow was CNY 270.77 million, resulting in a net cash outflow of CNY -50.71 million[35]. - The ending balance of cash and cash equivalents was CNY 136.05 million, down from CNY 274.43 million at the end of the previous year[35]. - The company reported a significant increase in cash paid for purchasing goods and services, totaling CNY 401.33 million, compared to CNY 679.37 million in the previous year[34]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,088,305,645.94, down 15.29% from the end of the previous year[4]. - The total assets decreased to CNY 3.09 billion in Q3 2021 from CNY 3.65 billion in the previous year, a decline of 15.4%[27]. - Total liabilities decreased to CNY 808.65 million in Q3 2021, down 35.6% from CNY 1.26 billion in Q3 2020[27]. - The company reported a significant increase in other receivables, rising from 59,199,305.44 RMB at the end of 2020 to 332,453,945.64 RMB by September 30, 2021[25]. - The company experienced a 203.49% increase in accounts receivable, attributed to delays in endorsing received notes[9]. Inventory and Costs - The company’s inventory decreased by 59.97% as a result of the sale of a subsidiary[9]. - The company’s inventory decreased from 288,579,821.77 RMB at the end of 2020 to 121,294,721.96 RMB by September 30, 2021, a decline of approximately 57.9%[25]. - The company’s operating costs decreased by 42.97%, primarily due to the reduction in the scope of consolidation after the sale of a subsidiary[12]. - Total operating costs for Q3 2021 were CNY 694.14 million, down 31.4% from CNY 1,012.71 million year-on-year[29]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,831[15]. - The largest shareholder, Liu Qun, holds 32.89% of the shares, amounting to 104,590,532 shares, with 35,000,000 shares pledged[15]. - The company has 10 major shareholders, with the first and eighth largest shareholders being brothers, indicating potential related party transactions[16]. Legal and Compliance Issues - The company is currently involved in a legal case regarding bribery, with a first-instance judgment imposing fines totaling 3.8 million RMB[17]. - The company did not conduct an audit for the third quarter report[37]. - The report indicates that the company has not made any adjustments related to the new leasing standards for the current year[36]. Investment and Restructuring - The company reported a significant increase in investment income of 13,597.49% due to the sale of a subsidiary[13]. - The company completed a major asset restructuring by selling 51% of the equity in Chongqing Pharmaceutical Group Changsheng Pharmaceutical Co., Ltd. on April 29, 2021[22]. - The company’s goodwill decreased by 31.53% following the sale of a subsidiary[9]. - The company’s financial expenses decreased by 87.81% due to the recovery of funds from the former chairman[13]. - Liu Qun has repaid a total of 12,147.4926 million RMB of misappropriated funds as of April 8, 2021[21].

Financial Performance - The company's operating revenue for the first half of 2021 was ¥495,001,560.78, a decrease of 18.82% compared to ¥609,742,876.06 in the same period last year[22]. - The net profit attributable to shareholders of the listed company was a loss of ¥40,479,749.05, an improvement of 40.90% from a loss of ¥68,491,029.81 in the previous year[22]. - The net cash flow from operating activities was negative at ¥67,621,441.88, a decline of 189.08% compared to a positive cash flow of ¥75,907,096.95 in the same period last year[22]. - Total assets at the end of the reporting period were ¥3,150,061,426.40, down 13.60% from ¥3,645,939,804.44 at the end of the previous year[22]. - The net assets attributable to shareholders of the listed company decreased by 1.73% to ¥2,299,903,043.93 from ¥2,340,360,125.72 at the end of the previous year[22]. - The basic and diluted earnings per share were both -¥0.1273, an improvement of 40.90% from -¥0.2154 in the same period last year[22]. - The weighted average return on net assets was -1.74%, an increase of 0.66% compared to -2.40% in the previous year[22]. - The company reported a total income of 14,042,379.14, with a tax impact of 1,989,162.02, indicating a robust financial performance[27]. - The company reported a total revenue of 9,303,252.2 yuan from the share buyback by the controlling shareholder, Liu Qun, who has increased his holdings by 1,628,800 shares[118]. - The company reported a total of CNY 1,009,695,105.86 in restricted assets, primarily due to bank acceptance bill guarantees and loan pledges[67]. Revenue and Cost Analysis - The company's total revenue for the reporting period was ¥495,001,560.78, representing a decrease of 18.82% compared to ¥609,742,876.06 in the same period last year[53]. - The cost of goods sold decreased by 25.46% to ¥319,590,145.02 from ¥428,725,085.01, primarily due to the sale of the subsidiary Changsheng Pharmaceutical[53]. - Total operating costs for the first half of 2021 were CNY 554,045,757.51, down 19.2% from CNY 686,233,701.08 in the same period last year[200]. - Operating costs included CNY 319,590,145.02 in cost of goods sold, a reduction of 25.5% from CNY 428,725,085.01 in the previous year[200]. Research and Development - Research and development expenses increased by 32.29% to ¥12,872,350.45, reflecting a rise in R&D investment compared to ¥9,730,479.34 in the previous year[53]. - The company emphasizes the importance of R&D and has established a dedicated research institute to enhance its innovation capabilities[82]. - The company is actively pursuing drug research and development, with several key projects in various stages, including sodium chloride injection and lidocaine hydrochloride injection currently under review[48]. - The company plans to optimize its R&D management and resource utilization to improve competitiveness and meet market demands[83]. Market and Industry Outlook - The pharmaceutical industry is experiencing growth due to increased healthcare demand, aging population, and ongoing medical reforms, indicating a positive outlook for the sector[30]. - The company has seen a significant increase in demand for its products, particularly in the context of the ongoing healthcare reforms and the expansion of the medical insurance catalog[30]. - The company is actively pursuing innovation in drug development, particularly in traditional Chinese medicine, which is gaining recognition and market potential[30]. - The company is expanding its market presence in Southeast Asia, with plans to enter three new countries by the end of 2021[161]. Corporate Governance and Compliance - The company emphasizes strict compliance with laws and regulations to protect the rights of shareholders and creditors, enhancing corporate governance and internal control systems[106]. - The company has strengthened its internal control management to ensure compliance with legal regulations and improve operational efficiency[46]. - The company plans to enhance internal controls and auditing processes to prevent future fund misappropriation[92]. - The company is committed to enhancing compliance management and adjusting operational strategies in response to regulatory changes[80]. Environmental Responsibility - Tian Sheng Pharmaceutical Group reported that its wastewater treatment facility operates normally, ensuring that wastewater is treated and meets standards before being discharged to the municipal sewage treatment plant[103]. - The company has implemented a comprehensive emergency response plan for environmental incidents to minimize risks from unexpected events[104]. - The company has established a monitoring scheme for environmental self-monitoring, entrusting qualified firms for oversight[104]. - The company emphasizes its commitment to social responsibility, focusing on economic benefits while protecting stakeholder interests[105]. Shareholder and Management Information - The company did not distribute cash dividends or issue new shares during the reporting period[97]. - There were no changes in the company's board of directors, supervisors, or senior management during the reporting period[96]. - The company has not implemented any employee stock ownership plans or other incentive measures during the reporting period[98]. - The company has a total of 106,152,524 restricted shares at the beginning of the period, with 103,157,316 shares at the end of the period[174]. Legal and Litigation Matters - The company is currently involved in ongoing litigation related to the former chairman Liu Qun, with the final judgment still uncertain[128]. - The company faced a lawsuit involving a bribery case with a potential liability of RMB 3.8 million, with a first-instance judgment imposing a fine of RMB 300,000[131]. - The company has ongoing litigation related to sales contract disputes, with a claim amount of RMB 85,000, which has not yet been executed[133]. - The company is involved in a commercial bill discounting dispute with a claim amount of RMB 18.35 million, where the defendant has won the case[133]. Strategic Initiatives - The company plans to invest 2,700 million CNY in infrastructure development to support its expansion strategy[161]. - A new technology platform is being developed, expected to launch in Q4 2021, which aims to streamline production processes and reduce costs by 15%[160]. - The company has completed a strategic acquisition of a local competitor for 1,500 million CNY, aimed at enhancing its market share[160]. - The company has established a comprehensive human resources management system and performance evaluation framework to enhance employee skills and promote mutual growth[108].

Financial Performance - The company's operating revenue for 2020 was CNY 1,202,746,111, a decrease of 28.39% compared to CNY 1,678,052,460 in 2019[20]. - The net profit attributable to shareholders was a loss of CNY 490,732,370, representing a 119.10% increase in loss compared to a loss of CNY 222,852,634 in 2019[20]. - The net profit excluding non-recurring gains and losses was a loss of CNY 147,308,288, a decrease of 41.69% compared to a loss of CNY 252,630,492 in 2019[20]. - The basic and diluted earnings per share were both CNY -1.5432, a 120.21% increase in loss compared to CNY -0.7008 in 2019[20]. - The weighted average return on equity was -18.57%, a decrease of 11.15% compared to -7.42% in 2019[20]. - Total assets decreased by 17.27% from 2019 to 2020, amounting to ¥3,645,939,800[21]. - Net profit attributable to shareholders decreased by 18.95% from 2019 to 2020, totaling ¥2,340,360,120[21]. - Operating revenue for 2020 was ¥1,202,746,111.67, down from ¥1,679,540,467.80 in 2019, representing a decline of approximately 28.5%[21]. - The company reported a negative net profit for all four quarters of 2020, with the largest loss in Q4 amounting to ¥371,429,930.37[25]. - The operating profit for the year was -¥500,342,805.23, representing a decline of 125.74% year-on-year[46]. - The company recognized a total asset impairment provision of ¥36,977.19 million across various asset categories due to the impact of the COVID-19 pandemic[46]. Cash Flow and Investments - The cash flow from operating activities increased by 31.06% to CNY 189,754,329 from CNY 144,208,286 in 2019[20]. - The company reported a net cash flow from operating activities of ¥60,695,403.94 in Q2 2020, which was the highest quarterly figure for the year[25]. - The total cash inflow from investment activities rose significantly by 103.98% to ¥218,620,388.34, while cash outflow increased by 25.04% to ¥294,770,145.53, resulting in a net cash flow from investment activities of -¥76,149,757.19, an improvement of 40.77% year-over-year[72]. - The net cash flow from financing activities decreased significantly by 298.26%, resulting in a net outflow of -¥134,571,476.36, compared to -¥33,790,020.35 in 2019[72]. - The company has made new investments, with long-term equity investments amounting to ¥2,000,000.00, marking a new strategic direction[78]. Business Operations and Strategy - The company has over 300 approved drug varieties, with key products including pediatric cough granules and erythromycin enteric-coated capsules[30]. - The company operates a complete industry chain encompassing drug manufacturing, circulation, and R&D[29]. - The company has established a nationwide marketing channel and logistics distribution network over nearly two decades, enhancing its distribution capabilities[42]. - The company is adapting to industry changes, focusing on three core strategies: quality, innovation, and talent development[46]. - The company plans to enhance its marketing strategy by integrating brand promotion with academic promotion to capture market share[48]. - The company is focusing on talent acquisition and professional training to support overall development and operational efficiency[51]. - The company has expanded its market presence beyond Chongqing to other provinces including Beijing, Sichuan, and Hubei[42]. Legal and Compliance Issues - The company is facing potential risks in its future operations as outlined in the report[6]. - The report includes a disclaimer that forward-looking statements do not constitute a commitment to investors[6]. - The company has not engaged in any investor communications or interviews during the reporting period[125]. - The company has faced risk warnings due to the legal issues involving its major shareholders, which may impact stock trading[121]. - The company is currently involved in an appeal regarding a public prosecution for bribery, with the final judgment still pending[134]. - The company has committed to enhancing internal controls and auditing processes to prevent future fund misappropriation[124]. - The company has not been subject to any significant legal disputes or investigations that would hinder the transfer of ownership rights[133]. Future Outlook and Growth Plans - The company plans to launch three new products in 2021, targeting a market share increase of 10% in the next fiscal year[142]. - The company aims to expand its market presence through strategic partnerships and new product development initiatives[84]. - The company provided a future outlook projecting a revenue growth of 10-12% for 2021, driven by new product launches and market expansion strategies[147]. - The company plans to increase R&D efforts in traditional Chinese medicine and chemical drugs, with short, medium, and long-term R&D plans[108]. - The company intends to restructure its sales operations in Chongqing and nationwide, aiming for rapid sales growth in its self-produced products[110]. - The company is exploring market expansion opportunities in Southeast Asia, targeting a 10% market share within the next three years[161]. Corporate Governance and Management - The company guarantees the establishment of an independent financial accounting department and independent bank accounts, ensuring compliance with tax regulations[153]. - The company has committed to maintaining independent operational activities, with the ability to autonomously manage assets and personnel[154]. - The company has pledged not to engage in any unauthorized use of its funds or assets, ensuring operational independence[154]. - The company emphasizes the importance of providing accurate and complete information to investors, with legal accountability for any misleading statements[155]. - The company is focused on maintaining a complete and independent governance structure, avoiding any institutional overlap with controlled enterprises[153]. Research and Development - The company has several key drug research projects in progress, including sodium chloride injection and lidocaine hydrochloride injection, all currently under review[52]. - Research and development expenses in 2020 were 22,456,265.11 yuan, down 38.11% from 36,286,833.93 yuan in 2019, representing 1.87% of total revenue[70]. - The company plans to invest 200 million yuan in new technology for production efficiency improvements over the next two years[157]. - The company is committed to maintaining a dividend payout ratio of 30% of net profits for the next three years[140].

Financial Performance - Revenue for Q1 2021 was CNY 334,030,966.92, representing a 14.37% increase compared to CNY 292,060,015.82 in the same period last year[9] - Net profit attributable to shareholders was a loss of CNY 25,296,030.22, a decrease of 223.42% from a loss of CNY 8,586,532.25 in the previous year[9] - Basic and diluted earnings per share were both CNY -0.0795, a decrease of 223.17% from CNY -0.0270 in the previous year[9] - The net profit for the first quarter was a loss of ¥25,263,753.07, compared to a loss of ¥9,088,220.38 in the same period last year, indicating a deterioration in financial performance[50] - Operating profit showed a loss of ¥24,773,886.05, compared to a loss of ¥8,296,173.68 in the previous year, indicating a worsening operational performance[50] Cash Flow - Net cash flow from operating activities was a negative CNY 29,219,215.98, down 320.56% from a positive CNY 15,211,693.01 in the same period last year[9] - The cash flow from operating activities was ¥356,239,837.53, down from ¥391,328,440.17, reflecting a decrease of about 9.0%[57] - The net cash flow from operating activities was -29,219,215.98 CNY, compared to 13,247,526.54 CNY in the previous period, indicating a significant decline[58] - The net cash flow from investment activities was -11,698,259.70 CNY, compared to 22,529,403.69 CNY in the previous period, showing a significant decline[62] - The company reported a net increase in cash and cash equivalents of -14,960,165.71 CNY, compared to -11,498,118.33 CNY in the previous period, indicating a worsening cash position[59] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,606,974,611.25, a decrease of 1.07% from CNY 3,645,939,804 at the end of the previous year[9] - Current liabilities decreased to CNY 815,032,434.34 from CNY 909,661,158.25, indicating a reduction of about 10.4%[42] - The total liabilities stood at CNY 1,242,428,805.86, a decrease from CNY 1,256,225,878.85, reflecting a decline of approximately 1.1%[42] - The equity attributable to shareholders decreased to CNY 2,315,159,728.37 from CNY 2,340,360,125.72, a decline of about 1.1%[43] - The company’s total non-current liabilities increased to CNY 427,396,371.52 from CNY 346,564,720.60, indicating a growth of about 23.3%[42] Expenses - Total operating costs increased to ¥365,980,206.32 from ¥318,054,324.43, representing a growth of approximately 15.1% year-over-year[49] - Research and development expenses rose to ¥6,091,352.39, up from ¥4,029,596.06, marking a significant increase of about 51.2%[49] - The company reported a significant increase in sales expenses, which rose to ¥90,266,812.17 from ¥66,139,703.49, an increase of about 36.4%[49] - Other income decreased to ¥8,054,026.46 from ¥19,028,747.87, a decline of approximately 57.7%[49] Shareholder and Corporate Governance - The number of ordinary shareholders at the end of the reporting period was 18,568[13] - The company received a criminal judgment requiring the defendant Liu Qun to repay a total of RMB 91.824926 million for funds misappropriated from the company, with additional responsibilities assigned to other defendants[18] - Liu Qun has repaid a total of RMB 121.474926 million, including RMB 3.6 million already returned, to resolve the issue of misappropriated funds[19] - The company’s stock has been under risk warning since June 5, 2019, due to the misappropriation of funds by the controlling shareholder[20] - The controlling shareholder Liu Qun has increased his shareholding by 1,628,800 shares, amounting to RMB 9.3032522 million, but still has an outstanding commitment to increase by 1,551,200 shares[25] Investments and Projects - As of March 31, 2021, the company has invested RMB 479.70 million in the oral solid preparation GMP technology transformation project, achieving an investment progress of 83.75%[29] - The Tian Sheng (Chongqing) Modern Pharmaceutical Logistics Headquarters Base project has seen a cumulative investment of RMB 138.81 million, also with an investment progress of 83.75% as of March 31, 2021[29] - The company raised a total of RMB 1,185.61 million by issuing 53 million shares at a price of RMB 22.37 per share, with a net amount of RMB 1,078.79 million after deducting issuance costs[29] - The company utilized RMB 65 million of idle raised funds to temporarily supplement working capital during the reporting period[29] - The company has engaged in wealth management with idle raised funds amounting to RMB 40 million, with no overdue amounts reported[31]

Group 1: Event Details - The event is titled "Chongqing District 2020 Investor Online Collective Reception Day" [1] - Scheduled for November 26, 2020, from 15:00 to 16:30 [1] - Investors can participate via the "Panorama · Roadshow World" platform [1] Group 2: Company Participation - Senior management of Tian Sheng Pharmaceutical Group will engage in online communication with investors [1] - The format of the interaction will be "one-to-many" [1] Group 3: Purpose and Assurance - The event aims to enhance the standardized operation level of listed companies and improve investor relations management [1] - The company guarantees the authenticity, accuracy, and completeness of the disclosed information [1]